- AU$256.62m
- AU$235.66m
- AU$0.58m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 5.79 | ||
| PEG Ratio (f) | 0.09 | ||
| EPS Growth (f) | 159.36% | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 35.8 | ||
| Price to Tang. Book | 35.8 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 288.64 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -134.32% | ||
| Return on Equity | -524.68% | ||
| Operating Margin | -2621.81% | ||
Financial Summary
| Year End 30th Jun | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | AU$m | 0 | 0 | 0 | 0.04 | 0.58 | 4.8 | 36.5 | 100.27% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | +49.15 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Dimerix Limited is an Australia-based clinical-stage biopharmaceutical company. The Company is focused on developing lives of patients with inflammatory diseases, including both kidney and respiratory diseases. It develops and commercializes patient preferred pharmaceutical products for global markets using its receptor technology to identify and develop drugs in areas with an unmet need. The Company is focused on developing its Phase III product candidate DMX-200 (QYTOVRA), for Focal Segmental Glomerulosclerosis (FSGS) kidney disease and is also developing DMX-700 for Chronic Obstructive Pulmonary Disease (COPD). Its Receptor Heteromer Investigation Technology (Receptor-HIT) is a scalable and globally applicable technology platform enabling the understanding of receptor interactions to rapidly screen and identify new drug opportunities. Its products target multiple global territories, with the initial focus predominantly on the United States and European markets.
Directors
- James Williams NEC (45)
- Nina Webster CEO
- Hamish George CFO
- Kathryn Harrison COO
- David Packham OTH
- Ash Soman EXB
- Hugh Alsop NED
- Sonia Poli NED (53)
- Last Annual
- June 30th, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- May 13th, 1975
- Public Since
- July 5th, 1989
- No. of Shareholders
- 6,823
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
Australian Stock Exchange - SEATS- Shares in Issue
- 557,866,917
- Address
- 425 Smith Street, Fitzroy, MELBOURNE, 3065
- Web
- https://dimerix.com/
- Phone
- +61 300813321
- Contact
- Nina Webster
- Auditors
- Stantons International
Upcoming Events for DXB
Similar to DXB
Actinogen Medical
Australian Stock Exchange - SEATS
Adalta
Australian Stock Exchange - SEATS
Algorae Pharmaceuticals
Australian Stock Exchange - SEATS
Alterity Therapeutics
Australian Stock Exchange - SEATS
Amplia Therapeutics
Australian Stock Exchange - SEATS
FAQ
What is the Dimerix share price?
As of Today at 01:15 UTC, shares in Dimerix are trading at AU$0.46. This share price information is delayed by 15 minutes.
How has the Dimerix share price performed this year?
Shares in Dimerix last closed at AU$0.46 and the price had moved by +41.54% over the past 365 days. In terms of relative price strength the Dimerix share price has outperformed the ASX All Ordinaries Index by +40.84% over the past year.
What are the analyst and broker recommendations for Dimerix?
The overall consensus recommendation for Dimerix is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Dimerix dividend yield?
Dimerix does not currently pay a dividend.
Does Dimerix pay a dividend?
Dimerix does not currently pay a dividend.
When does Dimerix next pay dividends?
Dimerix does not currently pay a dividend.
How do I buy Dimerix shares?
To buy shares in Dimerix you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Dimerix?
As of the previous close price of AU$0.46, shares in Dimerix had a market capitalisation of AU$256.62m.
Where are Dimerix shares listed?
Here are the trading details for Dimerix:
- Country of listing: Australia
- Exchange: ASX
- Ticker Symbol: DXB
What kind of share is Dimerix?
Based on an overall assessment of its quality, value and momentum Dimerix is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Dimerix share price forecast for 2025?
We could not find analyst target price data for this security.
Find out moreWhat is the trend in the Dimerix share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Dimerix. Over the past six months, its share price has outperformed the ASX All Ordinaries Index by +15.38%.
As of the last closing price of AU$0.46, shares in Dimerix were trading +5.48% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Dimerix PE Ratio?
The Dimerix PE ratio based on its reported earnings over the past 12 months is 5.79. The shares last closed at AU$0.46.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Dimerix?
Dimerix's management team is headed by:
- James Williams - NEC
- Nina Webster - CEO
- Hamish George - CFO
- Kathryn Harrison - COO
- David Packham - OTH
- Ash Soman - EXB
- Hugh Alsop - NED
- Sonia Poli - NED